Icon
+91 94997 68112
Login Register

Kengreal - (50 mg/Vial; Powder, Intravenous)

Cangrelor Chiesi U.S.A
50 mg/Vial; Powder, Intravenous
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor
Yes
***** *** * **** *** **** ******* - ***** ****** *** *** ****. ********** *** ******* **** **** ****, ***** *** ***** ** ********** ****** *******. ** ****** *** ******** ** ****** ******* *** ********** ** ****** '*** *** ****** ******** *******. ***** *** ***** * **** *** ** ****** '***, ***** ***** ** ** ******* ** ******** ********* ***** ****** ****** ****** ** *** ******.
Kengreal Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
***** ****** ******* ******* ******* ******* ******* ******* ******* *******
***-**** ********* ******* ********* ******* ******* ********* ******* *******
***** ****** **** *** ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** *** \ ********* ***** **, **** ******* **** ******* *** **** *** *** ****
***-**** *** \ ********* ***** **, **** ******* **** ******* *** **** *** *** ****
***** ****** ** \ ** *** **, **** ******* **** ******* *** **** *** *** ****
  1. *** **, **** : *** **** ******** ****** *** ***** **'* **** ** ****** ** *** ******* ****** ******* (**** **, ****)
  2. *** **, **** : ***** ****** ******** ****** *** ***** **'* **** ** ****** ** ****** ******* (**** **, ****)
  3. *** **, **** : ****** ***** * **** ******* ***** ****** ** ****** ******* (**** **, ****)
  4. *** **, **** : ****** ***** * **** ******* *** **** ** *** ******* ****** ******* (**** **, ****)
  5. *** **, **** :
  6. *** **, **** : ****** ***** * **** ******* **** ** *** ******* ****** ******* (**** **, ****)
  7. *** *, **** : ****** ***** * **** ******* ***** ****** ** *** ******* ****** ******* (**** **, ****) *** ******* (**** **, ****)
  8. *** **, **** : ***** ******* ** ******** ******* *** ********* *** **** **** ***.
  9. *** **, **** :
  10. *** **, **** : ****** ******* **** *** *** **** ** ******* *,***,***; *,***,***; *,***,***; *,***,***; *** **,***,***. ***** *** ********** ** ** *** ******* ** ****** **** ** *** ********** ** ** ******* *** ********** **** '*** *** '*** ***** ** *********.
  11. *** **, **** : ****** ******* ********** **** ***** ***** *** ***** ** ********** *** *******.
  12. *** **, **** : ***** ******** ****** ** *** ****-** ****** **** ******* ’***, ’***, ’***, ’***, ’***, ’***, *** ’*** *** * **** *** ** '***
  13. *** *, **** : ****** **** ***** **** ************ ** ******* ’***, ’***, ’***, ’***, ’***, ’***, *** ’***
  14. *** **, **** : ****** ******* ********** **** ***** ** ******* *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.